After Eli Lilly announced it received a Complete Response Letter, or CRL, from the FDA for its biologic license application for Mirikizumab for ulcerative colitis, or UC, Morgan Stanley tells investors that while the news is "disappointing" and the firm has pushed out expectations for the U.S. launch to 2024 from the second half of 2023, the company does not currently anticipate any impact on the supply of other products in the portfolio and the firm expects a limited impact to the stock given that the expected push out has a less than 1% impact on its 2023/2024 revenue estimates. Morgan Stanley has an Overweight rating and $445 price target on Eli Lilly shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LLY:
- Eli Lilly receives complete response letter from FDA for mirikizumab
- Eli Lilly price target lowered to $392 from $395 at Guggenheim
- Eli Lilly price target raised to $448 from $444 at Morgan Stanley
- Weight-loss business upended by popularity of ozempic, other drugs, WSJ reports
- JPMorgan sees favorable risk/rewards for Eli Lilly, Biogen into data